sk&f 81297 has been researched along with dizocilpine maleate in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Boldry, RC; Chase, TN; Kask, AM; Papa, SM | 1 |
Bartlett, MJ; Falk, T; Flores, AJ; Heien, ML; Parent, KL; Polt, R; Porreca, F; Root, BK; Sherman, SJ | 1 |
2 other study(ies) available for sk&f 81297 and dizocilpine maleate
Article | Year |
---|---|
MK-801 reverses effects of chronic levodopa on D1 and D2 dopamine agonist-induced rotational behavior.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Dizocilpine Maleate; Dopamine Agents; Dopamine Agonists; Ergolines; Excitatory Amino Acid Antagonists; Levodopa; Male; Oxidopamine; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation; Stereotyped Behavior; Sympatholytics | 1995 |
The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Benzazepines; Dizocilpine Maleate; Drug Synergism; Dyskinesia, Drug-Induced; Glycopeptides; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats | 2018 |